Edition:
United Kingdom

People: Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

10.00USD
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
$10.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
110,381
52-wk High
$15.91
52-wk Low
$8.66

Harfstrand, K. Anders 

Dr. K. Anders O. Harfstrand, M.D. Ph.D. is Independent Director of the Company. He is Chairman of Härfstrand Consulting AG (a pharmaceutical/biotechnology consulting firm), which he founded in 2010. Dr. Härfstrand also served as Chief Executive Officer of BBB Therapeutics BV (a biopharmaceutical company) from 2014 to 2015. Prior to that, he was President and Chief Executive Officer, Europe of Makhteshim Agan Industries Ltd. (an agrichemicals company) from 2013 to 2014; President and Chief Executive Officer of Humabs BioMed SA (a biotechnology company) from 2011 to 2012; and Chief Executive Officer of Nitec Pharma AG (a biopharmaceutical company) from 2007 to 2010. Dr. Härfstrand serves as a director of Karolinski Development AB (a biopharmaceutical investment company). He also served in various executive and management roles at Serono, Pfizer and Pharmacia, and in non-executive roles on a number of Supervisory Boards in Europe. Dr. Härfstrand earned his M.D. and Ph.D. in neuropharmacology endocrinology from Karolinska Institute in Sweden. He has served on our Board since 2015.

Basic Compensation

Total Annual Compensation, USD 60,871
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 435,067
Fiscal Year Total, USD 495,938

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lars Ekman

526,938

Gene Kinney

5,148,240

Tran Nguyen

3,260,720

Karin Walker

--

Wagner Zago

--

Arthur Homan

2,479,620
As Of  31 Dec 2017